Clinical Trial Update: Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial comparing IPX054 to immediate-release carbidopa-levodopa in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Carbidopa/Levodopa (Immediate Release) (carbidopa/levodopa IR)
• IPX054 (IPX054)

Snippet

Sponsor: Impax Laboratories, LLC | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED